The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

In both models, each agent alone provided roughly equivalent anti-tumor activity; however, there was a highly significant increase in anti-tumor activity when both agents were combined.

also in 132,142 other papers